Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 28 · inside the Ichimoku cloud · RSI 48 · MACD below its signal
None of the 29 investors followed here reported a position in CARL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CARL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Bertolini JeffreyChief Operating Officer | Conversion of Exercise of derivative security at price 5.92 per share. | 747 | $4.42K |
| Oct 4, 2026 | Bertolini JeffreyChief Operating Officer | Sale at price 14.39 per share. | 747 | $10.75K |
| Sep 29, 2026 | Bertolini JeffreyChief Operating Officer | Conversion of Exercise of derivative security at price 2.23 per share. | 243 | $542 |
| Sep 29, 2026 | Bertolini JeffreyChief Operating Officer | Sale at price 13.99 per share. | 243 | $3.40K |
| Sep 27, 2026 | Heppenstall RichardChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 89.3K | — |
| Jun 2, 2026 | Young Philip MDirector | Stock Award(Grant) at price 0.00 per share. | 13.7K | — |
| Jun 2, 2026 | Root Jonathan DDirector | Stock Award(Grant) at price 0.00 per share. | 13.7K | — |
| Jun 2, 2026 | Sidow KevinDirector | Stock Award(Grant) at price 0.00 per share. | 13.7K | — |
| Jun 2, 2026 | O'Boyle Kevin CDirector | Stock Award(Grant) at price 0.00 per share. | 13.7K | — |
| Mar 2, 2026 | Cordonnier MichaelChief Executive Officer | Conversion of Exercise of derivative security at price 0.34 - 4.35 per share. | 391.7K | $264.84K |
| Mar 1, 2026 | Cordonnier MichaelChief Executive Officer | Sale at price 13.29 per share. | 197.9K | $2.63M |
| Jan 27, 2026 | Greenstein Leonard MChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Jan 27, 2026 | Durall William ScottOfficer | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Jan 27, 2026 | Casey NiallOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Jan 27, 2026 | Cordonnier MichaelChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 117.3K | — |
| Jul 23, 2025 | Young Philip MDirector | Purchase at price 15.00 per share. | 60K | $899.99K |
| Jul 23, 2025 | Root Jonathan DDirector | Purchase at price 15.00 per share. | 466.7K | $7.00M |
| Jul 23, 2025 | Sidow KevinDirector | Purchase at price 15.00 per share. | 13.3K | $200.00K |
| Jul 23, 2025 | Mittendorff Robert E. IiDirector | Purchase at price 15.00 per share. | 1.33M | $20.00M |
| Jul 23, 2025 | Presidio Management Group Xii L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 15.00 per share. | 200K | $3.00M |
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Buy / hold / sell counts